EUCTR2005-000217-35-NO进行中（未招募）1 期
EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma
Rikshospitalet-Radiumhospitalet HF0 个研究点目标入组 1,200 人开始时间: 2006年1月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patologisk verifisert RMS.
- •Diagnose stilt i løpet av de siste 8 ukene.
- •Alder 0-21 år (6 mnd-21 år for intervensjonsstudien).
- •Ubehandlet bortsett fra primær kirurgi.
- •Patologi-preparater tilgjengleig for central review.
- •Tilgjengelig for oppfølging.
- •Signert samtykkeskjema.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ikke patologisk verifikasjon av RMS.
- •Diagnose stilt for mer enn 8 uker siden.
- •Tidligere påvist evt behandlet for malign sykdom.
- •Annen sykdom som kan blokkere behandling, eks hjertesvikt.
- •Alder <6 måneder eller > 21 år ved randomiseringstidspunkt.
- •RMS i lavrisk-gruppen.
- •RMS i standardrisk-gruppen.
- •RMS i veldig høyrisk-gruppen.
- •Manglende signert samtykkeskjema.
- •Ikke mulighet for oppfølging.
研究者
相似试验
进行中（未招募）
不适用
Treatment of children and young people presenting with non-metastatic rhabdomyosarcoma.EUCTR2005-000217-35-BEHôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.)600
进行中（未招募）
不适用
RMS 2005: a protocol for non metastatic rhabdomyosarcomarhabdomyosarcoma no metastaticMedDRA version: 14.1Level: PTClassification code 10039022Term: RhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000217-35-ESDr Jose Sanchez de Toledo Codina700
Unknown
4 期
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in ChildrenRhabdomyosarcomaNCT00339118Sheba Medical Center
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCEUCTR2021-002641-15-SEPoint BioPharma Inc.390
招募中
3 期
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu- PNT2002 PSMA Therapy After Second-line Hormonal Treatment10027655prostate cancerNL-OMON54469POINT BioPharma,30